HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Favre-Felix, N. Articles by Bonnotte, B. Search for Related Content PubMed PubMed Citation Articles by Favre-Felix, N. Articles by Bonnotte, B. Pubmed/NCBI databases Substance via MeSH

Cutting Edge: The Tumor Counterattack Hypothesis Revisited: Colon Cancer Cells Do Not Induce T Cell Apoptosis Via the Fas (CD95, APO-1) Pathway¹

Department of Biology and Therapy of Cancer, Institut National de la Santé et de la Recherche Médicale U 517, Faculty of Medicine and Pharmacy, Dijon, France

The counterattack hypothesis, suggesting that cancer cells express Fas ligand (FasL) and are able to kill Fas-expressing tumor-infiltrating activated T cells, was supported by reports of the killing of Jurkat cells by FasL-expressing human colon cancer cell lines. Through the use of an improved cytotoxic assay in which soluble FasL and FasL-transfected KFL9 cells were used as positive controls, we show that none of seven human colon cancer cell lines induce apoptosis of two Fas-expressing target cell lines, Jurkat and L1210-Fas cells. Moreover, in coculture experiments, cancer cell monolayers do not inhibit the growth of Fas-expressing lymphoid cells. Although FasL mRNA and protein were detected in the extracts of the colon cancer cell lines, flow cytometry and confocal microscopy failed to detect the protein on the surface of tumor cells. These results suggest that the counterattack of tumor-infiltrating T lymphocytes by cancer cells may not account for immune tolerance toward tumor cells.

This article has been cited by other articles:

				A. B. Frey and N. Monu Effector-phase tolerance: another mechanism of how cancer escapes antitumor immune response J. Leukoc. Biol., April 1, 2006; 79(4): 652 - 662. [Abstract] [Full Text] [PDF]

				J Strater, U Hinz, C Hasel, U Bhanot, G Mechtersheimer, T Lehnert, and P Moller Impaired CD95 expression predisposes for recurrence in curatively resected colon carcinoma: clinical evidence for immunoselection and CD95L mediated control of minimal residual disease Gut, May 1, 2005; 54(5): 661 - 665. [Abstract] [Full Text] [PDF]

				F. Donskov, H. von der Maase, N. Marcussen, S. Hamilton-Dutoit, H. H. T. Madsen, J. J. Jensen, and M. Hokland Fas Ligand Expression in Metastatic Renal Cell Carcinoma During Interleukin-2 Based Immunotherapy: No In vivo Effect of Fas Ligand Tumor Counterattack Clin. Cancer Res., December 1, 2004; 10(23): 7911 - 7916. [Abstract] [Full Text] [PDF]

				J. C. Murray, P. Symonds, W. Ward, M. Huggins, A. Tiga, K. Rice, Y. M. Heng, I. Todd, and R. A. Robins Colorectal Cancer Cells Induce Lymphocyte Apoptosis by an Endothelial Monocyte-Activating Polypeptide-II-Dependent Mechanism J. Immunol., January 1, 2004; 172(1): 274 - 281. [Abstract] [Full Text] [PDF]

				A. Gati, N. Guerra, C. Gaudin, S. Da Rocha, B. Escudier, Y. Lecluse, A. Bettaieb, S. Chouaib, and A. Caignard CD158 Receptor Controls Cytotoxic T-Lymphocyte Susceptibility to Tumor-Mediated Activation-Induced Cell Death by Interfering with Fas Signaling Cancer Res., November 1, 2003; 63(21): 7475 - 7482. [Abstract] [Full Text] [PDF]

				K Leelawat, T Watanabe, M Nakajima, S Tujinda, C Suthipintawong, and V Leardkamolkarn Upregulation of tumour associated antigen RCAS1 is implicated in high stages of colorectal cancer J. Clin. Pathol., October 1, 2003; 56(10): 764 - 768. [Abstract] [Full Text] [PDF]

				G. Andreola, L. Rivoltini, C. Castelli, V. Huber, P. Perego, P. Deho, P. Squarcina, P. Accornero, F. Lozupone, L. Lugini, et al. Induction of Lymphocyte Apoptosis by Tumor Cell Secretion of FasL-bearing Microvesicles J. Exp. Med., May 20, 2002; 195(10): 1303 - 1316. [Abstract] [Full Text] [PDF]

				M. Kurooka, G. J. Nuovo, M. A. Caligiuri, and G. J. Nabel Cellular Localization and Function of Fas Ligand (CD95L) in Tumors Cancer Res., March 1, 2002; 62(5): 1261 - 1265. [Abstract] [Full Text] [PDF]

				I. Medana, Z. Li, A. Flugel, J. Tschopp, H. Wekerle, and H. Neumann Fas Ligand (CD95L) Protects Neurons Against Perforin- Mediated T Lymphocyte Cytotoxicity J. Immunol., July 15, 2001; 167(2): 674 - 681. [Abstract] [Full Text] [PDF]

				T. S. Gourley and C.-H. Chang Cutting Edge: The Class II Transactivator Prevents Activation-Induced Cell Death by Inhibiting Fas Ligand Gene Expression J. Immunol., March 1, 2001; 166(5): 2917 - 2921. [Abstract] [Full Text] [PDF]